Navigation Links
KaloBios' Targeted Antibacterial KB001-A to be Featured in BIO 2013 Panel Discussion of "New Defenses Against Old Enemies"
Date:4/17/2013

SOUTH SAN FRANCISCO, Calif., April 17, 2013 /PRNewswire/ -- KaloBios Pharmaceuticals (Nasdaq: KBIO) today announced that David Pritchard , President and Chief Executive Officer, will speak at the BIO 2013 International Convention in Chicago, IL on Tuesday, April 23 as part of a panel entitled, "New Defenses Against Old Enemies: Vaccines and Biotherapies for Bacterial Infection."

(Logo: http://photos.prnewswire.com/prnh/20130225/MM66380LOGO)

Mr. Pritchard will be discussing the company's targeted antibacterial agent against Pseudomonas aeruginosa (Pa), KB001-A. KaloBios is developing KB001-A for the management of Pa in the lungs of patients with cystic fibrosis, while the company's corporate partner Sanofi Pasteur is developing KB001-A for the prevention of ventilator-associated pneumonia caused by Pa.

Breakout Session: Innovations and Opportunities in Vaccines
Session ID 1877: New Defenses Against Old Enemies: Vaccines and Biotherapies for Bacterial Infection
When: Tuesday, April 23, 2013, 9:00 – 10:15 AM
Where: McCormick Place, Room S402A

About KaloBios

KaloBios Pharmaceuticals, Inc. is developing a portfolio of patient-targeted, first-in-class monoclonal antibodies to treat serious medical conditions with a primary clinical focus on respiratory diseases and cancer.  For more information on KaloBios Pharmaceuticals, please visit our web site at http://www.kalobios.com.

Contact:
Jeffrey H. Cooper
Chief Financial Officer
KaloBios Pharmaceuticals, Inc.
(650) 243-3146
ir@kalobios.com

Media Contact:
Joan E. Kureczka
Kureczka/Martin Associates
Tel:  (415) 821-2413
Mobile: (415) 690-0210
Joan@Kureczka-Martin.com


'/>"/>
SOURCE KaloBios Pharmaceuticals
Copyright©2012 PR Newswire.
All rights reserved

Related medicine technology :

1. KaloBios to Present at Future Leaders in the Biotech Industry Conference
2. Bioassociate Announces Initiation of Coverage on KaloBios Pharmaceuticals, Inc.
3. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma
4. KaloBios Presents Clinical Results with Anti-GM-CSF Antibody in Persistent Asthma Data from KB002 Phase 1/2 Study Presented at the American Academy of Allergy, Asthma and Immunology Meeting
5. KaloBios Pharmaceuticals Completes Initial Public Offering
6. KaloBios Pharmaceuticals Announces Pricing of Initial Public Offering
7. Merrimack Pharmaceuticals Preclinical Research Shows MM-111 Restores Sensitivity To Chemotherapy And HER2-targeted Treatment In Gastric Cancer Model
8. Novelos Therapeutics Presents Diapeutic Technology Platform At EMIT: Targeted Radiotherapy International Conference
9. Launch Of Premium-priced, Novel Targeted Therapies Will Drive Growth In The Acute Leukemia Markets Beginning In 2015
10. Actinium Pharmaceuticals to Present at EMIT Targeted Radiotherapy Conference
11. Unilifes Bolus Injector Platform Targeted by Global Pharmaceutical Company for Use in Multi-Drug Program
Post Your Comments:
*Name:
*Comment:
*Email:
(Date:2/11/2016)... , Feb. 11, 2016 Scientists ... cell-isolation method that opens the door to genetic ... now have been impossible to isolate with 100 ... isolate specific tumor types in various stages of ... variants of these cells that are clinically relevant, ...
(Date:2/11/2016)... 11, 2016  Aytu BioScience, Inc. (OTCQX: AYTU), a ... and related conditions, announced today that the Company will ... of 2016 on Tuesday, February 16, 2016, at 4:30 ... provide an overview of its business and growth strategy, ... ended December 31, 2015. --> ...
(Date:2/11/2016)... CARLSBAD, Calif. , Feb.11, 2016  Ionis Pharmaceuticals, Inc. ... a live webcast on Thursday, February 25 at 11:30 a.m. ... on pipeline and business progress. www.ionispharma.com . ... at the same address. --> www.ionispharma.com . A ... the same address. --> Interested parties may listen ...
Breaking Medicine Technology:
(Date:2/11/2016)... Irving, Texas (PRWEB) , ... February 11, 2016 ... ... for plastic surgery, dermatology and women’s health, is pleased to announce the promotions ... Practice Development Partners sales team, Steve Catone to executive vice president of North ...
(Date:2/11/2016)... Washington, DC (PRWEB) , ... February 11, 2016 ... ... announce an upcoming Feb. 23 webinar, “Intel’s Direct-to-Employee Benefit Model: A Case Study ... a not-for-profit Catholic health care system that’s partnering with Intel on value-based health ...
(Date:2/11/2016)... ... February 11, 2016 , ... ... nominations seeking candidates for the Board of Commissioners. Individuals interested in volunteer board ... experience with diversity of clinical practice settings and across allied health to contribute ...
(Date:2/11/2016)... ... 2016 , ... PharmMD CEO Robert Yeager announced ... on contract negotiations, corporate strategy and healthcare data law. Additional responsibilities will include ... data breaches for the Part D Star Rating improvement and Medication Therapy Management ...
(Date:2/11/2016)... Orange City, FL (PRWEB) , ... February 11, ... ... has announced the commencement of a master charity program created to assist the ... every 60 days, working closely with nonprofit organizations and community leaders. Their hope ...
Breaking Medicine News(10 mins):